GlassScriptPhysician profile
Tarun K Sharma
NPI 1033138029
$8,534.43
in general payments reported to CMS, 2019-2025
25 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $977 · 2021: $739 · 2022: $959 · 2023: $1,135 · 2024: $2,000 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,897.35 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $1,098.50 | 2019-2025 | Linzess, Mavyret |
| Qol Medical, LLC | $844.54 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $505.25 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $492.82 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $465.29 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $445.46 | 2019-2024 | Linzess |
| Intra-Sana Laboratories | $434.73 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| E.R. Squibb & Sons, L.L.C. | $347.02 | 2021-2024 | Zeposia |
| Pfizer INC. | $322.32 | 2023-2025 | |
| Redhill Biopharma INC. | $190.41 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $188.08 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.33 | 2019-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $163.54 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $153.94 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $144.07 | 2021-2025 | |
| Allergan, INC. | $125.08 | 2019 | |
| Shionogi INC | $123.67 | 2022 | |
| Braintree Laboratories, INC. | $112.86 | 2019-2022 | |
| Celgene Corporation | $110.81 | 2021-2024 | Zeposia |
| Ucb, INC. | $102.48 | 2019 | |
| Madrigal Pharmaceuticals | $34.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Exact Sciences Corporation | $19.20 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $15.10 | 2022 | |
| Alfasigma USA, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.